Krystal Biotech, Inc. operates as a biotechnology company, which engages in developing and commercializing pharmaceutical products. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 275 full-time employees. The company went IPO on 2017-09-20. The firm is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
Follow-Up Questions
What is Krystal Biotech Inc (KRYS)'s P/E Ratio?
The P/E ratio of Krystal Biotech Inc is 61.2822
Who is the CEO of Krystal Biotech Inc?
Mr. Krish Krishnan is the Chairman of the Board of Krystal Biotech Inc, joining the firm since 2016.
What is the price performance of KRYS stock?
The current price of KRYS is $192.02, it has decreased 2.94% in the last trading day.
What are the primary business themes or industries for Krystal Biotech Inc?
Krystal Biotech Inc belongs to Biotechnology industry and the sector is Health Care
What is Krystal Biotech Inc market cap?
Krystal Biotech Inc's current market cap is $5.5B
Is Krystal Biotech Inc a buy, sell, or hold?
According to wall street analysts, 13 analysts have made analyst ratings for Krystal Biotech Inc, including 6 strong buy, 10 buy, 2 hold, 0 sell, and 6 strong sell
